EGFR and schwannoma: More importantly, the NRG1 ligand and its target the ERBB family receptors have been implicated in schwannoma tumorigenesis (40, 41, 42) leading to preclinical testing of EGFR/ERBB2 kinase inhibitor lapatinib in a vestibular schwannoma model (27).